The abstract is read at the publisher; the summary is JClub's.
Mezigdomide treatment of multiple myeloma bone marrow samples significantly reduces dysfunctional T-cell populations expressing exhaustion markers such as TIGIT.
- Why it matters: T-cell dysfunction contributes to multiple myeloma progression and to failure of antimyeloma CAR-T and bispecific T-cell engager therapies, but the mechanisms are not fully understood.
- What they did: The study used patient bone marrow samples plus primary T-cell in vitro models and epigenomic profiling (ATAC-seq, ChIP-seq, high-throughput chromatin conformation capture, RNA-seq) to link Ikaros to TIGIT regulation, and tested CAR-T in vivo.
- The result: Mezigdomide improves T-cell function and cytotoxicity in vitro and enhances survival outcomes of anti-B-cell maturation antigen CAR-T therapy in vivo, implying Ikaros-mediated exhaustion gene upregulation is abrogated.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.
- 1 cited this week
- Open access